Cargando…

The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report

Immune checkpoint inhibitors have made remarkable breakthroughs in the treatment of lung cancer, bringing significant survival benefits to the patients. A number of adverse events aggravated by immunotherapy in patients with pre-existing autoimmune diseases have been reported in the past, especially...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Zhiru, Xu, Yinghui, Zu, Jianjiao, Wang, Xu, Sun, Chao, Qiu, Shi, Guo, Ye, Ma, Kewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424493/
https://www.ncbi.nlm.nih.gov/pubmed/36052082
http://dx.doi.org/10.3389/fimmu.2022.946829
_version_ 1784778233570394112
author Gao, Zhiru
Xu, Yinghui
Zu, Jianjiao
Wang, Xu
Sun, Chao
Qiu, Shi
Guo, Ye
Ma, Kewei
author_facet Gao, Zhiru
Xu, Yinghui
Zu, Jianjiao
Wang, Xu
Sun, Chao
Qiu, Shi
Guo, Ye
Ma, Kewei
author_sort Gao, Zhiru
collection PubMed
description Immune checkpoint inhibitors have made remarkable breakthroughs in the treatment of lung cancer, bringing significant survival benefits to the patients. A number of adverse events aggravated by immunotherapy in patients with pre-existing autoimmune diseases have been reported in the past, especially skin toxicity, such as rash, pruritus, erythema, and vitiligo. However, whether the exacerbated autoimmune disease is reversible and when it will return to its original state after immunotherapy discontinuation is still inconclusive. In our report, we described a patient diagnosed with non-small cell lung cancer whose vitiligo was stable for about 10 years. We followed up and observed the patient’s skin depigmentation for the complete time window, from aggravation of application anti-programmed cell death-1 receptor antibody (anti-PD-1 antibody) to recovery after the withdrawal. We presented the objective images at particular time points using reflectance confocal microscopy and wood’s light. We found that the use of anti-PD-1 antibody aggravated in skin toxicity, but it was reversible, the time window from the beginning to recovery status was approximately 9 months. We used this real case scenario to explain the relationships between immunotherapy and autoimmune diseases.
format Online
Article
Text
id pubmed-9424493
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94244932022-08-31 The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report Gao, Zhiru Xu, Yinghui Zu, Jianjiao Wang, Xu Sun, Chao Qiu, Shi Guo, Ye Ma, Kewei Front Immunol Immunology Immune checkpoint inhibitors have made remarkable breakthroughs in the treatment of lung cancer, bringing significant survival benefits to the patients. A number of adverse events aggravated by immunotherapy in patients with pre-existing autoimmune diseases have been reported in the past, especially skin toxicity, such as rash, pruritus, erythema, and vitiligo. However, whether the exacerbated autoimmune disease is reversible and when it will return to its original state after immunotherapy discontinuation is still inconclusive. In our report, we described a patient diagnosed with non-small cell lung cancer whose vitiligo was stable for about 10 years. We followed up and observed the patient’s skin depigmentation for the complete time window, from aggravation of application anti-programmed cell death-1 receptor antibody (anti-PD-1 antibody) to recovery after the withdrawal. We presented the objective images at particular time points using reflectance confocal microscopy and wood’s light. We found that the use of anti-PD-1 antibody aggravated in skin toxicity, but it was reversible, the time window from the beginning to recovery status was approximately 9 months. We used this real case scenario to explain the relationships between immunotherapy and autoimmune diseases. Frontiers Media S.A. 2022-08-16 /pmc/articles/PMC9424493/ /pubmed/36052082 http://dx.doi.org/10.3389/fimmu.2022.946829 Text en Copyright © 2022 Gao, Xu, Zu, Wang, Sun, Qiu, Guo and Ma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Gao, Zhiru
Xu, Yinghui
Zu, Jianjiao
Wang, Xu
Sun, Chao
Qiu, Shi
Guo, Ye
Ma, Kewei
The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report
title The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report
title_full The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report
title_fullStr The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report
title_full_unstemmed The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report
title_short The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report
title_sort time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: a case report
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424493/
https://www.ncbi.nlm.nih.gov/pubmed/36052082
http://dx.doi.org/10.3389/fimmu.2022.946829
work_keys_str_mv AT gaozhiru thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT xuyinghui thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT zujianjiao thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT wangxu thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT sunchao thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT qiushi thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT guoye thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT makewei thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT gaozhiru timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT xuyinghui timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT zujianjiao timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT wangxu timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT sunchao timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT qiushi timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT guoye timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport
AT makewei timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport